Need an investment idea? Check out Popular Stocks and S2O Stock Screener.

Market Price

32.60 

0.07 0.2%

as of May 26 '23

52 Week Range:

0.07 41.21


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is developing xB3, a platform technology for the transport of therapeutic agents across the blood-brain barrier (BBB); and the treatment of central nervous system disorders (CNS), including brain cancers, and metabolic and neurodegenerative diseases. The company's in-house development programs develop symptomatic and disease-modifying treatments for brain metastases (xB3-001), glioblastoma (xB3-002), and neurodegenerative diseases (xB3-007). It has research collaborations with Aposense Limited to focus on the delivery of siRNA therapeutics for CNS disorders; Oxyrane UK Ltd. to focus on combining xB3 technology and Oxyrane's OxyCAT platform to deliver an undisclosed enhanced enzyme replacement therapy into the brain; and Janssen Biotech, Inc. to research, develop, and commercialize novel products based on Bioasis' xB3 platform. The company also has a research collaboration and license agreement with Neuramedy Co Ltd. to research, develop, and commercialize an xB3TM version of its antibody, Tomaralimab. Bioasis Technologies Inc. was incorporated in 2006 and is headquartered in New Haven, Connecticut.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Feb '12 Feb '13 Feb '14 Feb '15 Feb '16 Feb '17 Feb '18 Feb '19 Feb '20 Feb '21 Feb '22
Equity (BVPS) 0.06
0.10
0.07
0.06
0.02
0.01
0.04
0.01
-0.03
0.01
growth rate 66.7% -30.0% -14.3% -66.7% -50.0% 300.0% -75.0% -100.0% 100.0%
Earnings BIT -2.94
-4.96
-3.64
-2.84
-2.56
-2.99
-5.28
-4.86
-4.60
0.38
-3.60
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% -100.0%
Avg.PE -6.80
-4.10
-4.10
-4.10
-18.07
-15.79
-15.79
-15.79
-15.79
-15.79
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
ROA -125.26
-165.83
-112.57
-118.42
-117.90
-183.27
-455.08
-234.29
-302.15
33.11
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0%
ROE -133.24
-177.77
-120.64
-129.04
-138.17
-287.21
growth rate 0.0% 0.0% 0.0% 0.0% 0.0%
ROIC -133.37
-178.71
-121.67
-129.92
-138.58
-287.74
growth rate 0.0% 0.0% 0.0% 0.0% 0.0%
Cur. Ratio 6.97
13.48
10.98
8.38
3.97
0.98
1.01
1.09
0.26
1.61
growth rate 93.4% -18.6% -23.7% -52.6% -75.3% 3.1% 7.9% -76.2% 519.2%
Quick Ratio 6.87
13.39
10.61
8.01
3.81
0.81
0.90
1.08
0.24
1.46
growth rate 94.9% -20.8% -24.5% -52.4% -78.7% 11.1% 20.0% -77.8% 508.3%
Leverage 1.08
1.07
1.08
1.10
1.25
3.05
2.81
8.05
growth rate -0.9% 0.9% 1.9% 13.6% 144.0% -7.9% 42.0%
Balance Sheet Feb '12 Feb '13 Feb '14 Feb '15 Feb '16 Feb '17 Feb '18 Feb '19 Feb '20 Feb '21 Feb '22
Acct.Receivable 0.00
0.00
0.14
0.01
0.03
0.06
0.03
0.01
0.01
0.03
0.10
growth rate -89.4% 109.0% 91.4% -41.9% -71.2% 38.1% 126.1% 222.4%
Acct.Payable 0.19
0.21
0.30
0.56
0.79
1.00
1.99
1.84
1.49
growth rate 10.9% 46.3% 85.4% 41.5% 26.8% 99.4% -7.4% -19.2%
Cur.Assets 1.10
3.30
2.05
1.73
1.72
0.73
0.79
1.38
0.65
3.06
2.11
growth rate 200.0% -38.0% -15.5% -0.4% -57.6% 8.5% 74.2% -52.9% 369.5% -31.1%
Total Assets 2.10
3.80
2.58
2.21
2.15
1.11
1.22
1.74
0.94
3.28
2.27
growth rate 81.0% -32.1% -14.2% -2.7% -48.4% 10.0% 42.7% -46.0% 247.9% -30.8%
Cash 1.00
1.70
1.09
1.34
0.77
0.55
0.68
1.36
0.58
2.74
1.73
growth rate 70.0% -35.8% 22.6% -42.3% -28.3% 22.3% 100.6% -57.6% 374.8% -36.8%
Inventory 0.00
growth rate
Cur.Liabilities 0.20
0.20
0.19
0.21
0.43
0.75
0.79
1.26
2.48
1.90
2.99
growth rate 0.0% -6.8% 10.8% 110.0% 72.4% 5.4% 60.3% 96.1% -23.3% 57.4%
Liabilities 0.20
0.20
0.19
0.21
0.43
0.75
0.79
2.29
3.43
2.87
4.18
growth rate 0.0% -6.2% 10.0% 110.0% 72.4% 5.4% 190.7% 49.7% -16.3% 45.8%
LT Debt 0.00
0.52
0.06
0.40
growth rate -88.8% 595.2%
Equity 2.00
3.60
2.39
2.01
1.72
0.36
0.43
-0.55
-2.49
0.41
-1.92
growth rate 80.0% -33.6% -16.1% -14.3% -78.9% 19.5% -100.0% 0.0% 100.0% -100.0%
Common Shares 33.00
38.00
41.00
43.00
44.00
45.00
22.79
24.20
25.42
27.26
27.45
growth rate 15.2% 7.9% 4.9% 2.3% 2.3% -49.4% 6.2% 5.0% 7.2% 0.7%
Cash Flow Statement Feb '12 Feb '13 Feb '14 Feb '15 Feb '16 Feb '17 Feb '18 Feb '19 Feb '20 Feb '21 Feb '22
Capital Expenditures 0.03
0.00
0.00
0.00
0.04
0.04
0.00
growth rate -83.7% 0.0% 212.5% 1,640.0% 0.0% -95.2%
Cash Dividends 0.00
growth rate
Cash From OA -1.78
-2.82
-2.02
-1.53
-1.24
-3.67
-3.23
-3.30
1.77
-3.64
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% -100.0%
FCF per Share -0.06
-0.06
-0.05
-0.06
-0.04
-0.03
-0.06
-0.07
-0.06
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Sale Purchase of Stock 1.47
1.93
1.52
0.18
3.90
growth rate 31.1% -21.4% -88.4% 2,121.0%
FCF -2.00
-2.00
-3.00
-2.00
-2.00
-1.00
-4.00
-3.00
-3.00
2.00
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0%
Income Statement Feb '12 Feb '13 Feb '14 Feb '15 Feb '16 Feb '17 Feb '18 Feb '19 Feb '20 Feb '21 Feb '22
Sales 0.00
0.37
0.51
0.59
1.42
0.61
4.08
0.04
growth rate 39.0% 15.0% 141.1% -57.4% 572.5% -99.1%
Op.Income -2.90
-5.00
-3.64
-2.84
-2.56
-2.99
-5.28
-4.86
-4.60
0.38
-3.60
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% -100.0%
IBT -2.90
-5.00
-3.61
-2.84
-2.57
-2.99
-5.31
-3.47
-4.06
0.70
-2.96
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% -100.0%
Net Income -2.90
-5.00
-3.61
-2.84
-2.57
-2.99
-5.31
-3.47
-4.06
0.70
-2.96
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% -100.0%
EPS -0.09
-0.13
-0.09
-0.07
-0.06
-0.07
-0.10
-0.06
-0.07
0.01
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0%
Gross Profit 0.00
-0.05
0.08
0.12
1.41
0.61
4.08
0.04
growth rate 100.0% 46.8% 1,057.1% -57.0% 572.5% -99.1%
R&D 1.10
1.90
2.00
1.35
0.84
0.78
0.95
1.95
2.03
1.24
1.23
growth rate 72.7% 5.3% -32.5% -37.8% -6.8% 20.8% 106.4% 4.1% -39.1% -1.0%

Quarterly Statements

Item Name May '21 Aug '21 Nov '21 Feb '22 May '22
Earnings BIT -0.79
-1.19
-0.78
-0.85
-0.63
growth rate 0.0% 0.0% 0.0% 0.0%
Balance Sheet May '21 Aug '21 Nov '21 Feb '22 May '22
Acct.Receivable 0.05
0.05
0.06
0.10
0.17
growth rate 4.9% 27.9% 61.2% 78.2%
Acct.Payable 1.64
1.45
1.22
1.49
1.20
growth rate -11.7% -15.9% 22.2% -19.2%
Cur.Assets 2.15
3.86
2.83
2.11
1.14
growth rate 79.1% -26.5% -25.6% -45.7%
Total Assets 2.35
4.04
3.01
2.27
1.29
growth rate 71.8% -25.7% -24.6% -43.1%
Cash 1.87
3.53
2.59
1.73
0.77
growth rate 88.3% -26.5% -33.3% -55.8%
Cur.Liabilities 1.75
2.61
2.72
2.99
3.03
growth rate 49.3% 4.1% 10.0% 1.2%
Liabilities 2.40
4.35
4.56
4.18
3.43
growth rate 80.9% 5.0% -8.4% -17.9%
LT Debt 0.65
1.11
0.40
0.27
growth rate 70.2% -63.8% -32.0%
Equity -0.05
-0.31
-1.56
-1.92
-2.15
growth rate 0.0% 0.0% 0.0% 0.0%
Common Shares 27.26
27.26
27.26
27.45
27.45
growth rate 0.0% 0.0% 0.7% 0.0%
Cash Flow Statement May '21 Aug '21 Nov '21 Feb '22 May '22
Capital Expenditures
growth rate
Cash From OA -0.80
-1.21
-0.95
-0.68
-0.59
growth rate 0.0% 0.0% 0.0% 0.0%
Sale Purchase of Stock
growth rate
FCF
growth rate
Income Statement May '21 Aug '21 Nov '21 Feb '22 May '22
Sales 0.04
growth rate
Op.Income -0.79
-1.19
-0.78
-0.85
-0.63
growth rate 0.0% 0.0% 0.0% 0.0%
IBT -0.54
-0.58
-1.27
-0.57
-0.23
growth rate 0.0% 0.0% 0.0% 0.0%
Net Income -0.54
-0.58
-1.27
-0.57
-0.23
growth rate 0.0% 0.0% 0.0% 0.0%
EPS
growth rate
Gross Profit 0.04
growth rate
R&D 0.20
0.40
0.30
0.32
0.18
growth rate 102.3% -25.2% 6.4% -43.7%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

F (0.00)

YOY Growth Grade:

F (0.00)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 17.27 2,963.64 -2.38
EPS / Growth 0.0% 0.01

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 1.0%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 0.0% 0.5% 0.5%
Future PE 0.00 0.51 0.51
Future EPS 0.01 0.01 0.01
Value Price
MOS %
0.00
-100.0%
0.00
-100.0%
0.00
-100.0%
MOS Price 0.00 0.00 0.00
IRT 99.00 99.00 99.00

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.